---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107741"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:49:01.426520+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elutia Q3 revenue $3.3M, closes $88M BioEnvelope sale to Boston Scientific, pays off debt

## Summary
- Net sales $3.3M (down from $3.7M YoY); loss from operations $5.2M vs $9.2M loss a year ago.
- Closed sale of BioEnvelope business to Boston Scientific for $88M; used $27.8M to repay SWK loan facility in full.
- Advancing NXT-41x for plastic/reconstructive surgery; FDA clearance of base matrix expected 2H26, drug-eluting version 1H27.
- Cash balance $4.7M at Sep 30, 2025; received $80.3M net proceeds on Oct 1, 2025 after closing and escrow.
- Settled 7 additional FiberCel cases, leaving only 6 unresolved; Guido J. Neels appointed to Board.

## SEC filing metadata
- accession: 0001104659-25-107741
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465925107741/0001104659-25-107741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465925107741/tm2530506d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107741
- JSON: https://secwatch.observer/filing/0001104659-25-107741.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.